Gitoformate (INN, or pentaformylgitoxin, trade name Dynocard) is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat).[1] Produced by Madaus, it is not available in the US, and does not seem to be available in Europe either.

Chemistry

Gitoxigenin, the aglycon

Gitoformate is a derivative of the glycoside gitoxin, with five of the six free hydroxyl groups formylated, one on the aglycon and four on the sugar.[2][3] Gitoxin, a cardiac glycoside from the woolly foxglove (Digitalis lanata), has an aglycon of the cardenolide type named gitoxigenin, which is also the aglycon of lanatoside B, another Digitalis lanata glycoside.[4]

References

  1. ^ Rietbrock N, Woodcock BG, Hrazdil U (1984). "[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]". Arzneimittel-Forschung. 34 (8): 915–917. PMID 6541927.
  2. ^ Dei Cas L, Affatato A, Buia E, Casciarri G, Faggiano P, Giunti G, et al. (1984). "[Plasma levels of gitoxin (by RIA and rubidium-86 uptake) and systolic time after treatment with a single dose of gitoformate]". Cardiologia. 29 (5–6): 291–300. PMID 6542412.
  3. ^ "Gitoxin". PubChem. U.S. National Library of Medicine.
  4. ^ Foye WO, Lemke TL, Williams DA (2008). Foye's principles of medicinal chemistry. Lippincott Williams & Wilkins. p. 699. ISBN 978-0-7817-6879-5.